VC-backed Kronos Bio goes public
San Mateo, California-based Kronos Bio, a clinical-stage biopharmaceutical company, has raised about $250 million for its IPO after pricing its over 13.1 million shares at $19 per share.
9 October 2020•3 mins read
San Mateo, California-based Kronos Bio, a clinical-stage biopharmaceutical company, has raised about $250 million for its IPO after pricing its over 13.1 million shares at $19 per share.
